Concepedia

The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance

G. W. J. Frederix, J. G. Coen van Hasselt, Jan H.M. Schellens, Anke M. Hövels, Jan A. M. Raaijmakers, Alwin D. R. Huitema, Johan L. Severens

PharmacoEconomics · 2013 · 32 citations · 41 references

DOIFull text

Open access

Concepts

References

41

R: A Language and Environment for Statistical Computing

R Core Team · 2000 · 353K citations · Full text

, , +10

Tamoxifen for early breast cancer: an overview of the randomised trials

The Lancet · 1998 · 4.1K citations

, , +9

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Anthony Howell, Jack Cuzick, M Baum et al. · The Lancet · 2005 · 2.3K citations

, , +6

Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

Katrina Bauer, Monica Brown, Rosemary D. Cress et al. · Cancer · 2007 · 2.1K citations

, , +11

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

Bruce G. Haffty, Qifeng Yang, Thomas Kearney et al. · Journal of Clinical Oncology · 2006 · 1.1K citations · Full text

, , +16